Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
06/2005
06/15/2005CN1626123A Medication for treating dementia and preparation method
06/15/2005CN1626103A Combination of medication of containing general saponin of notoginseng and icariin as well as usage
06/15/2005CN1626095A Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-diol
06/15/2005CN1626094A Quetiapingranulater
06/15/2005CN1626093A Oxacarbazepine film-coated tablets
06/15/2005CN1626083A Powder and injection preparation of hydrochloric naloxone and preparation method
06/15/2005CN1626077A Treatment of nuerodegenerative diseases
06/15/2005CN1626069A Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of diabetic retinopathy
06/15/2005CN1206535C Modulating multiple lineage kinase proteins
06/15/2005CN1206230C 4-Pyridyl-and 2,4-pyrimidinyl-substituted pyrrole derivatives and their use in pharmacy
06/15/2005CN1206228C N-heterocyclic derivatives as NOS inhibitors
06/15/2005CN1206221C Acridine derivatives
06/15/2005CN1206210C Ethyl methyl 3-[(1S)-1-(dimethylamino)ethyl]phenyl] carbamate and its prepn and medicine use
06/15/2005CN1206207C Preparation method of cyanophthaofluoroaniline
06/15/2005CN1205991C Quick-acting Chinese patent medicine for treating sleeplessness
06/15/2005CN1205971C Naolejing granular preparation for brani health
06/15/2005CN1205937C Phosphatidic acid-comprising compositions
06/15/2005CN1205935C Highly selective norepinephrine reuptake inhibitors and methods of using same
06/15/2005CN1205912C Antiperspirant compositions
06/14/2005US6906177 Screening; psychological disorders, brain disorders, antiepileptic agents; genetic engineering
06/14/2005US6906175 Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor.
06/14/2005US6906174 Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor
06/14/2005US6906169 Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
06/14/2005US6906104 Aminediols for the treatment of Alzheimer's disease
06/14/2005US6906099 By administering a drug that increases central nervous system GABA (4-aminobutyric acid) levels; for example gabapentin, valproic acid, progabide, gamma- hydroxybutyric acid, fengabine, cetylGABA, topiramate, tiagabine, or acamprosate
06/14/2005US6906089 Kidney disease; cardiovascular disorders; antiscarring agents; wound healing agents
06/14/2005US6906087 Antidepressant; storage stability
06/14/2005US6906085 Tetrahydropyran derivatives as neurokinin receptor antagonists
06/14/2005US6906083 Alzheimer's disease; brain disorders
06/14/2005US6906081 For treatment of Alzheimer's disease, learning disabilities
06/14/2005US6906080 Antiinflammatory agents, analgesics, drug abuse, alcoholism
06/14/2005US6906079 Method and reagents for N-alkylating ureides
06/14/2005US6906062 Stable colour at ambient conditions of storage; treating psychological disorders
06/14/2005US6906053 Antiarthritic agents; antiulcer agents; osteoporosis; antiinflammatory agents; antitumor and anticancer agents
06/14/2005US6906041 Treatment of immune diseases
06/14/2005US6905855 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
06/14/2005US6905832 Uses of peptides derived from the cytoplasmic domain of the amyloid protein precursor (APP)
06/14/2005US6905688 Comprises therapeutic fusion proteins for diagnosis and treatment of cancers, neovascularization and autoimmune diseases
06/14/2005US6905678 Gene delivery vectors with cell type specificity for mesenchymal stem cells
06/14/2005CA2400318C Botulinum toxin pharmaceutical compositions
06/14/2005CA2361584C Anticonvulsant derivatives useful in treating autism
06/14/2005CA2339782C Polyamine treatment of neurological disorders
06/14/2005CA2327285C Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same
06/14/2005CA2304967C 4(3)substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
06/14/2005CA2150229C Nitric esters having a pharmacological activity and process for their preparation
06/14/2005CA2136008C Substituted (arylalkylaminobenzyl)amino-propionamide derivatives and process for their preparation
06/09/2005WO2005051912A1 Piperidine compound and method for producing same
06/09/2005WO2005021095A3 Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors
06/09/2005WO2005021003A3 Immunosuppressive effects of pteridine derivatives
06/09/2005WO2005014039A3 Active or passive immunization against proapoptotic neurotrophins for the treatment or prevention of neurodegenerative diseases
06/09/2005WO2004012671A3 Substituted furo [2,3-b] pyridine derivatives
06/09/2005US20050124817 Method for the preparation of citalopram
06/09/2005US20050124795 DNA encoding a human subunit 5-HT3-C of the 5-HT3 serotonin receptor
06/09/2005US20050124793 Novel proteins and dnas thereof
06/09/2005US20050124696 Cyclopenteneones for antiischemic agents, antiinflammatory agents and aging resistance
06/09/2005US20050124689 Tocopherol enriched compositions and amelioration of inflammatory symptoms
06/09/2005US20050124682 Such as N-{2-[5-(methylthio)-1H-indol-3-yl]ethyl}acetamide for treatment of disorders of the melatoninergic system; hormone replacement therapy
06/09/2005US20050124665 Cyclopenteneones for antiischemic agents, antiinflammatory agents and aging resistance
06/09/2005US20050124658 Decahydronaphtho[2,3-c]furan derivatives
06/09/2005US20050124654 Compounds and methods of use
06/09/2005US20050124649 Deazapurines and uses thereof
06/09/2005US20050124648 Triazolo-quinolin derivatives useful as adenosine receptor ligands
06/09/2005US20050124642 (1-Indanone)-(1,2,3,6-tetrahydropyridine) compounds
06/09/2005US20050124631 For example, 2-amino-7-chloro-6-hydroxy-4-methylbenzothiazole; compounds that prevent the formation of polyglutamine containing protein aggregates; treatment of spinal and bulbar muscular atrophy, dentatorubal pallidoluysian atrophy, spinocerebellar ataxia, Alzheimers disease
06/09/2005US20050124628 Quinoline and aza indole compounds having pharmacological activity, for example, 8-(4-Methyl-piperazin-1-yl)-3-phenylsulfonylquinoline; use in the treatment of CNS and other disorders
06/09/2005US20050124627 Use as excitatory amino acid antagonists for combating neurodegenerative and cerebrovascular diseases, epilepsy, schizophrenia, Alzheimer's, Parkinson's or Huntington's disease, or psychoses; for example, 3-[4-(3,4-methylenedioxybenzyl)piperidino]-N-(2-oxo-2,3-dihydrobenzoxazol-6-yl)propionamide
06/09/2005US20050124626 Novel compounds
06/09/2005US20050124622 Compounds and methods for the treatment of pain
06/09/2005US20050124621 Novel inhibitors of kinases
06/09/2005US20050124615 3-heteroarly-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b] indole-1-acetamide derivatives, preparation and use thereof in medicaments
06/09/2005US20050124606 Novel benzothiazine and benzothiadiazine derivatives method for preparing same and pharmaceutical compositions containing same
06/09/2005US20050124605 E.g., substituted 2,3,5,10b-tetraaza-benzo[e]azulen-6-yl)-acetic acids, 2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-5-yl)-(4,6-dimethoxy-pyrimidin-2-yloxy)-acetic acids and 2,3,4,5-tetrahydro-benzo[e][1,4]diazepin-1-ylmethyl}-benzoates; treating circulatory, inflammatory, and proliferative disorders
06/09/2005US20050124603 Heterocyclylindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands
06/09/2005US20050124577 8-Azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
06/09/2005US20050124574 Purine derivatives
06/09/2005US20050124554 Spermidine derivatives for the treatment of chronic neurodegenerative diseases
06/09/2005US20050124547 Tau-conotoxin peptides
06/09/2005US20050124007 Human mesencephalon cell lines and methods of use therefor
06/09/2005US20050124004 Histamine receptor h3 polynucleotides
06/09/2005US20050124003 Using immunoaffinity selection to isolate and propagate pluripotent stem cell populations from fetal developmental tissues; cell replacement therapies
06/09/2005US20050123999 Dihydroouabain-like factor and diagnostic & therapeutic compositions and methods
06/09/2005US20050123912 Nucleoprotein for use as tool in treatment, diagnosis and prevention of infection, cell proliferative, neurological, developmental, autoimmune and inflammatory disorders
06/09/2005US20050123897 Controlling flux of penetrants across adaptable, semipermeable porous barrier by enlarging applied dose per area; drug delivery kits, patches
06/09/2005US20050123671 Incorporating trehalose into an edible aqueous system containing alpha glucosyl hesperidin or catechin or both followed by sterilization
06/09/2005US20050123609 Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
06/09/2005US20050123576 Mupirocin compositions for topical use, an improved process of making same and methods of using same
06/09/2005US20050123575 Heating, cooling, reheating and recooling a mixture containing hard fat while stirring; cosmetics, cosmeceutical, pharmaceutical; second temperature is lower than the congelation temperature of the mixture; hard fat is a mixture of triester of glycerin with caprylic, capric and stearic acids
06/09/2005US20050123556 Vaccine against infectious disease
06/09/2005US20050123536 Treatment of immunological disorders using anti-dc30 antibodies
06/09/2005US20050123524 Pharmaceutical compositions and methods for treating neuronal damages and neurodegenerative diseases
06/09/2005US20050123512 Binding agents, vectors, host cells; gene therapy; nucleotide sequence with DNA insert encoding polypeptide; genetic engineering; medical diagnosis
06/09/2005US20050123508 human granulocyte colony stimulating factor polypeptides having amino acid replacements in the sequence, used for treating hematopoietic, neurological or reproductive disorders
06/09/2005DE4142157B4 Opioid-Peptide, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zusammensetzung Opioid peptides, process for their preparation and pharmaceutical composition containing the
06/09/2005CA2547467A1 Piperidine compound and method for producing same
06/09/2005CA2547444A1 7-[4-(4-chlorobenzyloxy) benzenesulfonyl]-8-methoxy-3-methyl-2,3,4,5-tetrahydro-1h-3-benzazepinium maleate or tosylate as antipsychotics
06/09/2005CA2547235A1 T-type calcium channel blocker
06/09/2005CA2546672A1 Use of c-(2-phenyl-cyclohexyl)-methylamine compounds for the treatment of anxiety disorders
06/09/2005CA2546395A1 Compositions and methods of treatment using l-type calcium channel blockers and cholinesterase inhibitors
06/09/2005CA2546366A1 Using of (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dymethyl-pyridine-3,5-dicarboxylate in the treatment of memory disorders
06/08/2005EP1537873A1 The pharmaceutical formulation of traditional chinese medicine for abstinence of drug and preparation method and use thereof
1 ... 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 ... 1833